Article
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
European journal of cancer (Oxford, England : 1990) - 1 Jul 2012
Bokemeyer Carsten, Van Cutsem Eric, Rougier Philippe, Ciardiello Fortunato, Heeger Steffen, Schlichting Michael, Celik Ilhan, Köhne Claus-Henning
Abstract excerpt
BACKGROUND: The CRYSTAL and OPUS randomised clinical trials demonstrated that adding cetuximab to first-line chemotherapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC) significantly improved treatment outcome compared with chemotherapy alone. The objective of this pooled analysis was to further investigate these findings in patients with KRAS wild-type tumours using extended survival data...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.